Header Logo

ZIJUN XU-MONETTE

TitleInstructor
InstitutionMD Anderson
DepartmentHematopathology
Address6900 Fannin
Houston TX 77030-3802
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Yu T, Xu-Monette ZY, Lagoo A, Shuai W, Wang B, Neff J, Carrillo LF, Carlsen ED, Pina-Oviedo S, Young KH. Flow cytometry quantification of tumor-infiltrating lymphocytes to predict the survival of patients with diffuse large B-cell lymphoma. Front Immunol. 2024; 15:1335689. PMID: 38348048; PMCID: PMC10859492.
      Citations:    Fields:    Translation:HumansCells
    2. Yu T, Xu-Monette ZY, Yu L, Li Y, Young KH. Correction: Mechanisms of ferroptosis and targeted therapeutic approaches in lymphoma. Cell Death Dis. 2024 Jan 09; 15(1):19. PMID: 38195601; PMCID: PMC10776675.
      Citations:    Fields:    
    3. Xu-Monette ZY, Li Y, Snyder T, Yu T, Lu T, Tzankov A, Visco C, Bhagat G, Qian W, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Hagemeister FB, Wang Y, Go H, Ponzoni M, Ferreri AJM, Moller MB, Parsons BM, Fan X, van Krieken JH, Piris MA, Winter JN, Au Q, Kirsch I, Zhang M, Shaughnessy J, Xu B, Young KH, Xu-Monette ZY, Li Y, Snyder T, Yu T, Lu T, Tzankov A, Visco C, Bhagat G, Qian W, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Hagemeister FB, Wang Y, Go H, Ponzoni M, Ferreri AJM, M?ller MB, Parsons BM, Fan X, van Krieken JH, Piris MA, Winter JN, Au Q, Kirsch I, Zhang M, Shaughnessy J, Xu B, Young KH. Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL. Clin Cancer Res. 2023 12 01; 29(23):4808-4821. PMID: 37728879; PMCID: PMC10842978.
      Citations: 2     Fields:    Translation:HumansCells
    4. Yu T, Xu-Monette ZY, Yu L, Li Y, Young KH. Mechanisms of ferroptosis and targeted therapeutic approaches in lymphoma. Cell Death Dis. 2023 11 25; 14(11):771. PMID: 38007476; PMCID: PMC10676406.
      Citations:    Fields:    Translation:HumansCells
    5. Sircar A, Singh S, Xu-Monette ZY, Coyle KM, Hilton LK, Chavdoula E, Ranganathan P, Jain N, Hanel W, Tsichlis P, Alinari L, Peterson BR, Tao J, Muthusamy N, Baiocchi R, Epperla N, Young KH, Morin R, Sehgal L. Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma. Leukemia. 2023 10; 37(10):2094-2106. PMID: 37598282; PMCID: PMC10539170.
      Citations:    Fields:    Translation:HumansCells
    6. Chung EYL, Sartori G, Ponzoni M, Cascione L, Priebe V, Xu-Monette ZY, Fang X, Zhang M, Visco C, Tzankov A, Rinaldi A, Sgrignani J, Zucca E, Rossi D, Cavalli A, Inghirami G, Scott DW, Young KH, Bertoni F. ETS1 phosphorylation at threonine 38 is associated with the cell of origin of diffuse large B cell lymphoma and sustains the growth of tumour cells. Br J Haematol. 2023 Oct; 203(2):244-254. PMID: 37584198.
      Citations:    Fields:    
    7. Lu T, Zhang J, Xu-Monette ZY, Young KH. The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma. Exp Hematol Oncol. 2023 Aug 14; 12(1):72. PMID: 37580826; PMCID: PMC10424456.
      Citations: 2     
    8. Al-Juhaishi T, Wang Y, Milton DR, Xu-Monette ZY, Jabbour E, Daher M, Im JS, Bashir Q, Iyer SP, Marin D, Olson AL, Popat U, Qazilbash M, Rondon G, Gulbis AM, Champlin RE, Young KH, Khouri IF. Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant. Bone Marrow Transplant. 2023 09; 58(9):1000-1007. PMID: 37198234.
      Citations:    Fields:    Translation:Humans
    9. Li Y, Xu-Monette ZY, Abramson J, Sohani AR, Bhagat G, Tzankov A, Visco C, Zhang S, Dybkaer K, Pan Z, Xu M, Tam W, Zu Y, Hsi ED, Hagemeister FB, Go H, van Krieken JH, Winter JN, Ponzoni M, Ferreri AJM, M?ller MB, Piris MA, Wang Y, Zhang M, Young KH. EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential. Blood Adv. 2023 04 11; 7(7):1308-1311. PMID: 36399513; PMCID: PMC10119604.
      Citations: 1     Fields:    Translation:Cells
    10. Pang Y, Lu T, Xu-Monette ZY, Young KH. Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma. Int J Mol Sci. 2023 Mar 13; 24(6). PMID: 36982568; PMCID: PMC10052731.
      Citations: 2     Fields:    Translation:HumansCells
    11. Yu T, Luo D, Luo C, Xu-Monette ZY, Yu L. Prognostic and therapeutic value of serum lipids and a new IPI score system based on apolipoprotein A-I in diffuse large B-cell lymphoma. Am J Cancer Res. 2023; 13(2):475-484. PMID: 36895983; PMCID: PMC9989605.
      Citations: 1     
    12. Yu F, He H, Nastoupil LJ, Xu-Monette ZY, Pham K, Liang Y, Chen G, Fowler NH, Yin CC, Tan D, Yang Y, Hu S, Young KH, Pham LV, You MJ. Targetable vulnerability of deregulated FOXM1/PLK1 signaling axis in diffuse large B cell lymphoma. Am J Cancer Res. 2022; 12(10):4666-4679. PMID: 36381323; PMCID: PMC9641390.
      Citations: 1     
    13. Liu W, Cai Q, Yu T, Strati P, Hagemeister FB, Zhai Q, Zhang M, Li L, Fang X, Li J, Sun R, Zhang S, Yang H, Wang Z, Qian W, Iwaki N, Sato Y, Oksenhendler E, Xu-Monette ZY, Young KH, Yu L. Clinical characteristics and outcomes of Castleman disease: a multicenter Consortium study of 428 patients with 15-year follow-up. Am J Cancer Res. 2022; 12(9):4227-4240. PMID: 36225639; PMCID: PMC9548017.
      Citations: 1     
    14. Yu T, Cai QQ, Zhai QL, Li L, Fang X, Li J, Sun R, Yang H, Wang Z, Qian W, Xu-Monette ZY, Young KH, Yu L. Analysis of albumin as a prognostic factor in HHV-8/HIV-negative Castleman disease from a multicenter study. Leuk Lymphoma. 2022 Sep 07; 1-10. PMID: 36074798.
      Citations:    
    15. Elfrink S, Ter Beest M, Janssen L, Baltissen MP, Jansen PWTC, Kenyon AN, Steen RM, de Windt D, Hagemann PM, Hess C, van Spronsen DJ, Hoevenaars B, van der Spek E, Xu-Monette ZY, Young KH, Kaffa C, Bervoets S, van Heek J, Hesius E, de Winde CM, Vermeulen M, van den Brand M, Scheijen B, van Spriel AB. IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphoma. Blood Adv. 2022 04 12; 6(7):2254-2266. PMID: 35086136; PMCID: PMC9006271.
      Citations:    Fields:    Translation:HumansCells
    16. Xu-Monette ZY, Wei L, Fang X, Au Q, Nunns H, Tzankov A, Zhu F, Visco C, Bhagat G, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Hagemeister FB, Sun X, Han X, Go H, Ponzoni M, Parsons BM, van Krieken JH, Winter JN, Li Y, Xu B, Albitar M, You H, Young KH, Nagy M, Ferreri AJM, M?ller MB, Piris MA. Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2022 Mar 01; 28(5):972-983. PMID: 34980601; PMCID: PMC9137388.
      Citations: 1     Fields:    Translation:Humans
    17. Albitar M, Zhang H, Goy A, Xu-Monette ZY, Bhagat G, Visco C, Tzankov A, Fang X, Zhu F, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Hagemeister FB, Huh J, Ponzoni M, Parsons BM, van Krieken JH, Winter JN, Li Y, Xu B, Young KH, Ferreri AJM, M?ller MB, Piris MA. Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. Blood Cancer J. 2022 02 01; 12(2):25. PMID: 35105854; PMCID: PMC8807629.
      Citations: 1     Fields:    Translation:HumansCells
    18. Liu H, Xu-Monette ZY, Tang G, Wang W, Kim Y, Yuan J, Li Y, Chen W, Li Y, Fedoriw GY, Zhu F, Fang X, Luedke C, Medeiros LJ, Young KH, Hu S. EBV+ high-grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a multi-institutional study. Histopathology. 2022 Feb; 80(3):575-588. PMID: 34637146.
      Citations:    Fields:    Translation:HumansCells
    19. Youssef Y, Karkhanis V, Chan WK, Jeney F, Canella A, Zhang X, Sloan S, Prouty A, Helmig-Mason J, Tsyba L, Hanel W, Zheng X, Zhang P, Chung JH, Lucas DM, Kauffman Z, Larkin K, Strohecker AM, Ozer HG, Lapalombella R, Zhou H, Xu-Monette ZY, Young KH, Han R, Nurmemmedov E, Nuovo G, Maddocks K, Byrd JC, Baiocchi RA, Alinari L. Transducin ?-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma. Haematologica. 2021 11 01; 106(11):2927-2939. PMID: 33054136; PMCID: PMC8561281.
      Citations: 2     Fields:    Translation:Humans
    20. Tian XP, Ma SY, Young KH, Ong CK, Liu YH, Li ZH, Zhai QL, Huang HQ, Lin TY, Li ZM, Xia ZJ, Zhong LY, Rao HL, Li M, Cai J, Zhang YC, Zhang F, Su N, Li PF, Zhu F, Xu-Monette ZY, Wong EKY, Ha JCH, Khoo LP, Ai L, Cheng RF, Lim JQ, de Mel S, Ng SB, Lim ST, Cai QQ. A composite single-nucleotide polymorphism prediction signature for extranodal natural killer/T-cell lymphoma. Blood. 2021 08 12; 138(6):452-463. PMID: 33728448.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    21. You H, Xu-Monette ZY, Wei L, Nunns H, Bhagat G, Fang X, Zhu F, Visco C, Tzankov A, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Hagemeister FB, Huh J, Ponzoni M, Parsons BM, Van Krieken JH, Piris MA, Li Y, Au Q, Xu B, Albitar M, Young KH, Nagy ML, Ferreri AJM, M?ller MB, Winter JN. Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma. Oncoimmunology. 2021; 10(1):1928365. PMID: 34350060; PMCID: PMC8293967.
      Citations: 3     Fields:    Translation:Humans
    22. Chen P, Redd L, Schmidt Y, Koduru P, Fuda F, Montgomery-Goecker C, Kumar K, Xu-Monette Z, Young K, Collins R, Chen W. MYC protein expression does not correlate with MYC abnormalities detected by FISH but predicts an unfavorable prognosis in de novo acute myeloid leukemia. Leuk Res. 2021 07; 106:106584. PMID: 33933715.
      Citations:    Fields:    Translation:Humans
    23. Yu X, Li W, Deng Q, Liu H, Wang X, Hu H, Cao Y, Xu-Monette ZY, Li L, Zhang M, Lu Z, Young KH, Li Y. MYD88 L265P elicits mutation-specific ubiquitination to drive NF-?B activation and lymphomagenesis. Blood. 2021 03 25; 137(12):1615-1627. PMID: 33025009; PMCID: PMC7995293.
      Citations: 7     Fields:    Translation:HumansCells
    24. Wang Y, Gali VL, Xu-Monette ZY, Sano D, Thomas SK, Weber DM, Zhu F, Fang X, Deng M, Zhang M, Hagemeister FB, Li Y, Orlowski RZ, Lee HC, Young KH. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenstr?m macroglobulinemia. Neoplasia. 2021 04; 23(4):361-374. PMID: 33735664; PMCID: PMC7985670.
      Citations: 2     Fields:    Translation:Humans
    25. Fang X, Sun Z, Xu-Monette ZY, Young KH. Predictive Model for Idiopathic Multicentric Castleman Disease Supporting Treatment Decisions. Oncologist. 2021 01; 26(1):4-6. PMID: 33215784; PMCID: PMC7794201.
      Citations:    Fields:    Translation:Humans
    26. Deng M, Xu-Monette ZY, Pham LV, Wang X, Tzankov A, Fang X, Zhu F, Visco C, Bhagat G, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, You H, Huh J, Ponzoni M, Parsons BM, Hagemeister F, van Krieken JH, Winter JN, Li Y, Xu B, Liu P, Young KH, Ferreri AJM, M?ller MB, Piris MA. Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. Mol Cancer Res. 2021 02; 19(2):249-260. PMID: 33154093; PMCID: PMC8092941.
      Citations: 5     Fields:    Translation:HumansCells
    27. Deng M, Zhang M, Xu-Monette ZY, Pham LV, Tzankov A, Visco C, Fang X, Bhagat G, Zhu F, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Choi WWL, Huh J, Ponzoni M, Parsons BM, van Krieken JH, Winter JN, Hagemeister F, Alinari L, Li Y, Andreeff M, Xu B, Young KH, Ferreri AJM, M?ller MB, Piris MA. XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. J Hematol Oncol. 2020 11 04; 13(1):148. PMID: 33148342; PMCID: PMC7641823.
      Citations: 10     Fields:    Translation:HumansCells
    28. Yu L, Shi M, Cai Q, Strati P, Hagemeister F, Zhai Q, Li L, Fang X, Li J, Sun R, Zhang S, Yang H, Wang Z, Qian W, Iwaki N, Sato Y, Zhang L, Li J, Xu-Monette ZY, Young KH, Oksenhendler E. A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study. Oncologist. 2020 11; 25(11):963-973. PMID: 32852137; PMCID: PMC7648372.
      Citations: 2     Fields:    Translation:HumansCells
    29. Chen K, Yang Q, Zha J, Deng M, Zhou Y, Fu G, Bi S, Feng L, Xu-Monette ZY, Chen XL, Fu G, Dai Y, Young KH, Xu B. Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia. Cell Death Dis. 2020 09 18; 11(9):778. PMID: 32948748; PMCID: PMC7501858.
      Citations: 4     Fields:    Translation:Humans
    30. Xu-Monette ZY, Young KH. Therapeutic vaccines for aggressive B-cell lymphoma. Leuk Lymphoma. 2020 12; 61(13):3038-3051. PMID: 32840404; PMCID: PMC8344075.
      Citations: 3     Fields:    Translation:Humans
    31. Liu M, Wang X, Li W, Yu X, Flores-Villanueva P, Xu-Monette ZY, Li L, Zhang M, Young KH, Ma X, Li Y. Targeting PD-L1 in non-small cell lung cancer using CAR T cells. Oncogenesis. 2020 Aug 13; 9(8):72. PMID: 32792499; PMCID: PMC7426958.
      Citations: 15     
    32. Xu-Monette ZY, Zhang H, Zhu F, Tzankov A, Bhagat G, Visco C, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, You H, Huh J, Ponzoni M, Parsons BM, van Krieken JH, Winter JN, Hagemeister FB, Shahbaba B, De Dios I, Zhang H, Li Y, Xu B, Albitar M, Young KH, Ferreri AJM, M?ller MB, Piris MA. A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. Blood Adv. 2020 07 28; 4(14):3391-3404. PMID: 32722783; PMCID: PMC7391158.
      Citations: 6     Fields:    Translation:HumansCells
    33. Zhou H, Xu-Monette ZY, Xiao L, Strati P, Hagemeister FB, He Y, Chen H, Li Y, Manyam GC, Li Y, Piris MA, Young KH, Montes-Moreno S. Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up. Blood Cancer J. 2020 05 04; 10(5):49. PMID: 32366834; PMCID: PMC7198569.
      Citations: 10     Fields:    Translation:HumansCells
    34. Yu X, Li W, Liu H, Deng Q, Wang X, Hu H, Xu-Monette ZY, Xiong W, Lu Z, Young KH, Wang W, Li Y. Ubiquitination of the DNA-damage checkpoint kinase CHK1 by TRAF4 is required for CHK1 activation. J Hematol Oncol. 2020 05 01; 13(1):40. PMID: 32357935; PMCID: PMC7193419.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    35. Keane C, Law SC, Gould C, Birch S, Sabdia MB, Merida de Long L, Thillaiyampalam G, Abro E, Tobin JW, Tan X, Xu-Monette ZY, Young KH, Gifford G, Gabreilli S, Stevenson WS, Gill A, Talaulikar D, Jain S, Hernandez A, Halliday SJ, Bird R, Cross D, Hertzberg M, Gandhi MK. LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma. Blood Adv. 2020 04 14; 4(7):1367-1377. PMID: 32267932; PMCID: PMC7160288.
      Citations: 27     Fields:    Translation:HumansCells
    36. Gallardo M, Malaney P, Aitken MJL, Zhang X, Link TM, Shah V, Alybayev S, Wu MH, Pageon LR, Ma H, Jacamo R, Yu L, Xu-Monette ZY, Steinman H, Lee HJ, Sarbassov D, Rapado I, Barton MC, Martinez-Lopez J, Bueso-Ramos C, Young KH, Post SM. Uncovering the Role of RNA-Binding Protein hnRNP K in B-Cell Lymphomas. J Natl Cancer Inst. 2020 01 01; 112(1):95-106. PMID: 31077320; PMCID: PMC7489062.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    37. Deng Q, Hu H, Yu X, Liu S, Wang L, Chen W, Zhang C, Zeng Z, Cao Y, Xu-Monette ZY, Li L, Zhang M, Rosenfeld S, Bao S, Hsi E, Young KH, Lu Z, Li Y. Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant. Nat Commun. 2019 11 07; 10(1):5061. PMID: 31699989; PMCID: PMC6838078.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    38. Xu-Monette ZY, Li J, Xia Y, Crossley B, Bremel RD, Miao Y, Xiao M, Snyder T, Manyam GC, Tan X, Zhang H, Visco C, Tzankov A, Dybkaer K, Bhagat G, Tam W, You H, Hsi ED, van Krieken JH, Huh J, Ponzoni M, Winter JN, Medeiros JT, Xu B, Li Y, Kirsch I, Young KH, Ferreri AJM, M?ller MB, Piris MA. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. J Immunother Cancer. 2019 10 22; 7(1):272. PMID: 31640780; PMCID: PMC6806565.
      Citations: 7     Fields:    Translation:HumansCells
    39. Wang L, Deng Q, Hu H, Liu M, Gong Z, Zhang S, Xu-Monette ZY, Lu Z, Young KH, Ma X, Li Y. Glyphosate induces benign monoclonal gammopathy and promotes multiple myeloma progression in mice. J Hematol Oncol. 2019 07 05; 12(1):70. PMID: 31277689; PMCID: PMC6612199.
      Citations: 4     Fields:    Translation:HumansAnimals
    40. Miao Y, Medeiros LJ, Xu-Monette ZY, Li J, Young KH. Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets. Front Oncol. 2019; 9:107. PMID: 30881917; PMCID: PMC6406015.
      Citations: 17     
    41. Xu-Monette ZY, Xiao M, Au Q, Padmanabhan R, Xu B, Hoe N, Torres-Ruiz R, Manyam GC, Visco C, Miao Y, Tan X, Zhang H, Tzankov A, Wang J, Tam W, You H, Bhagat G, Hsi ED, Ponzoni M, van Krieken JH, Winter JN, Westin JR, Pham LV, Medeiros LJ, Rassidakis GZ, Li Y, Freeman GJ, Young KH, Rodr?guez-Perales S, Dybk?r K, Ferreri AJM, M?ller MB, Piris MA. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. Cancer Immunol Res. 2019 04; 7(4):644-657. PMID: 30745366.
      Citations: 44     Fields:    Translation:HumansCells
    42. Li L, Sun R, Miao Y, Tran T, Adams L, Roscoe N, Xu B, Manyam GC, Tan X, Zhang H, Xiao M, Tzankov A, Visco C, Dybkaer K, Bhagat G, Tam W, Hsi ED, van Krieken JH, You H, Huh J, Ponzoni M, Zhang M, Winter JN, Medeiros LJ, Rassidakis GZ, Vaupel CA, Li Y, Dakappagari N, Xu-Monette ZY, Young KH, Ferreri AJM, M?ller MB, Piris MA. PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. Mod Pathol. 2019 06; 32(6):741-754. PMID: 30666052.
      Citations: 15     Fields:    Translation:HumansCells
    43. Wang L, Kumar M, Deng Q, Wang X, Liu M, Gong Z, Zhang S, Ma X, Xu-Monette ZY, Xiao M, Yi Q, Young KH, Ramos KS, Li Y. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces peripheral blood abnormalities and plasma cell neoplasms resembling multiple myeloma in mice. Cancer Lett. 2019 01; 440-441:135-144. PMID: 30343114; PMCID: PMC6238649.
      Citations: 4     Fields:    Translation:Animals
    44. Li L, Zhang J, Chen J, Xu-Monette ZY, Miao Y, Xiao M, Young KH, Wang S, Medeiros LJ, Wang M, Ford RJ, Pham LV. B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma. Blood. 2018 10 25; 132(17):1805-1817. PMID: 30209121; PMCID: PMC6634963.
      Citations: 29     Fields:    Translation:HumansCells
    45. Yin L, Xu-Monette ZY, Brock J, Li Y, Young KH. Different prevalence and clinical outcome of Epstein-Barr virus positive diffuse large B-cell lymphoma between North American and non-Western populations. Ann Transl Med. 2018 Jun; 6(11):236. PMID: 30023399; PMCID: PMC6036001.
      Citations: 2     
    46. Wang X, Cao X, Sun R, Tang C, Tzankov A, Zhang J, Manyam GC, Xiao M, Miao Y, Jabbar K, Tan X, Pang Y, Visco C, Xie Y, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WWL, van Krieken JH, Huh J, Ponzoni M, Parsons BM, Winter JN, Li S, Miranda RN, Medeiros LJ, Li Y, Xu-Monette ZY, Young KH, Ferreri AJM, M?ller MB, Piris MA. Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. Neoplasia. 2018 06; 20(6):574-593. PMID: 29734016; PMCID: PMC5994742.
      Citations: 22     Fields:    Translation:HumansCells
    47. Sarasquete ME, Panizo C, Morscio J, Martinez A, Alcoceba M, Fresquet V, Gonzalez-Farre B, Paiva B, Young KH, Robles EF, Roa S, Celay J, Larrayoz M, Rossi D, Gaidano G, Montes-Moreno S, Piris MA, Balanzategui A, Jimenez C, Rodriguez I, Calasanz MJ, Larrayoz MJ, Segura V, Yi S, Li J, Zhang M, Xu-Monette ZY, Puig-Moron N, Orfao A, Hernandez-Rivas JM, Miguel JS, Prosper F, Tousseyn T, Sagaert X, Gonzalez M, Martinez-Climent JA, Garc?a-Barchino MJ, Garcia-Mu?oz R, Rabasa MP, B?ttcher S. Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia. J Pathol. 2018 05; 245(1):61-73. PMID: 29464716.
      Citations: 12     Fields:    Translation:HumansCells
    48. Xu-Monette ZY, Zhang M, Li J, Young KH. PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response? Front Immunol. 2017; 8:1597. PMID: 29255458; PMCID: PMC5723106.
      Citations: 98     Fields:    
    49. Xu-Monette ZY, Zhou J, Young KH. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood. 2018 01 04; 131(1):68-83. PMID: 29118007; PMCID: PMC5755041.
      Citations: 144     Fields:    Translation:HumansAnimals
    50. Xu-Monette ZY, Yi S, Dabaja BS, Manyam GC, Westin J, Fowler N, Miranda RN, Zhang M, Ferry JA, Medeiros LJ, Harris NL, Young KH, Li X. Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center. Am J Surg Pathol. 2017 Oct; 41(10):1309-1321. PMID: 28817403.
      Citations: 8     Fields:    Translation:HumansCells
    51. Visco C, Wang J, Tisi MC, Deng L, D'Amore ESG, Tzankov A, Montes-Moreno S, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Piris MA, Medeiros LJ, Xu-Monette ZY, Young KH, Dybk?r K, Ferreri AJM, M?ller MB. Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations. Br J Cancer. 2017 Nov 21; 117(11):1685-1688. PMID: 28949959; PMCID: PMC5729442.
      Citations: 4     Fields:    Translation:HumansCells
    52. Yao Z, Deng L, Xu-Monette ZY, Manyam GC, Jain P, Tzankov A, Visco C, Bhagat G, Wang J, Dybkaer K, Tam W, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Winter JN, Fayad L, Liu Y, Song Y, Orlowski RZ, Kantarjian H, Medeiros LJ, Li Y, Cortes J, Young KH, M?ller MB, Piris MA. Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. Leukemia. 2018 02; 32(2):353-363. PMID: 28745330; PMCID: PMC5985660.
      Citations: 19     Fields:    Translation:Humans
    53. Jain N, Zhu H, Khashab T, Ye Q, George B, Mathur R, Singh RK, Berkova Z, Wise JF, Braun FK, Wang X, Patel K, Xu-Monette ZY, Young KH, Sehgal L, Samaniego F, Courty J. Targeting nucleolin for better survival in diffuse large B-cell lymphoma. Leukemia. 2018 03; 32(3):663-674. PMID: 28690315; PMCID: PMC5829046.
      Citations: 14     Fields:    Translation:HumansCells
    54. Wang J, Xu-Monette ZY, Jabbar KJ, Shen Q, Manyam GC, Tzankov A, Visco C, Wang J, Montes-Moreno S, Tam W, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Wang S, Piris MA, Medeiros LJ, Li Y, Pham LV, Young KH, Dybk?r K, Ferreri AJM, M?ller MB. AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. Am J Pathol. 2017 Aug; 187(8):1700-1716. PMID: 28627414; PMCID: PMC5530910.
      Citations: 21     Fields:    Translation:HumansCells
    55. Cai Q, Tu M, Xu-Monette ZY, Sun R, Manyam GC, Xu X, Tzankov A, Hsi ED, Medeiros LJ, Ok CY, Young KH, M?ller MB. NF-?B p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53. Mod Pathol. 2017 06; 30(6):854-876. PMID: 28281555.
      Citations: 6     Fields:    Translation:HumansCells
    56. Yu L, Tu M, Cortes J, Xu-Monette ZY, Miranda RN, Zhang J, Orlowski RZ, Neelapu S, Boddu PC, Akosile MA, Uldrick TS, Yarchoan R, Medeiros LJ, Li Y, Fajgenbaum DC, Young KH. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Blood. 2017 03 23; 129(12):1658-1668. PMID: 28100459; PMCID: PMC5364343.
      Citations: 50     Fields:    Translation:HumansCells
    57. Zhang M, Xu-Monette ZY, Li L, Manyam GC, Visco C, Tzankov A, Wang J, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Han van Krieken J, Huh J, Ponzoni M, Parsons BM, Winter JN, Piris MA, Medeiros LJ, Pham LV, Young KH, Ferreri AJ, M?ller MB. RelA NF-?B subunit activation as a therapeutic target in diffuse large B-cell lymphoma. Aging (Albany NY). 2016 12 08; 8(12):3321-3340. PMID: 27941215; PMCID: PMC5270671.
      Citations: 13     Fields:    Translation:HumansCells
    58. Pham LV, Bryant JL, Mendez R, Chen J, Tamayo AT, Xu-Monette ZY, Young KH, Manyam GC, Yang D, Medeiros LJ, Ford RJ. Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma. Oncotarget. 2016 Dec 06; 7(49):80599-80611. PMID: 27716624; PMCID: PMC5348344.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    59. Xu-Monette ZY, Li L, Byrd JC, Jabbar KJ, Manyam GC, Maria de Winde C, van den Brand M, Tzankov A, Visco C, Wang J, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Huh J, Ponzoni M, Parsons BM, Winter JN, Wang M, Hagemeister FB, Han van Krieken J, Medeiros LJ, Li Y, van Spriel AB, Young KH, Ferreri AJ, M?ller MB, Piris MA. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. Blood. 2016 12 29; 128(26):3083-3100. PMID: 27760757; PMCID: PMC5201094.
      Citations: 24     Fields:    Translation:HumansCells
    60. Mai Y, Yu JJ, Bartholdy B, Xu-Monette ZY, Knapp EE, Yuan F, Chen H, Ding BB, Yao Z, Das B, Zou Y, Young KH, Parekh S, Ye BH. An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL. Blood. 2016 12 15; 128(24):2797-2807. PMID: 27737889; PMCID: PMC5159702.
      Citations: 15     Fields:    Translation:HumansCells
    61. Xia Y, Xu-Monette ZY, Tzankov A, Li X, Manyam GC, Murty V, Bhagat G, Zhang S, Pasqualucci L, Visco C, Dybkaer K, Chiu A, Orazi A, Zu Y, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Winter JN, Westin J, Fowler N, Miranda RN, Ok CY, Li Y, Li J, Medeiros LJ, Young KH, M?ller MB, Piris MA. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. Leukemia. 2017 03; 31(3):625-636. PMID: 27568520; PMCID: PMC5837859.
      Citations: 27     Fields:    Translation:HumansCells
    62. Loghavi S, Wang SA, Medeiros LJ, Jorgensen JL, Li X, Xu-Monette ZY, Miranda RN, Young KH. Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology. Leuk Lymphoma. 2016 12; 57(12):2804-2812. PMID: 27105079; PMCID: PMC5142610.
      Citations: 7     Fields:    Translation:HumansCells
    63. Francisco M, Malatxeberria S, Montalban C, Garcia J, Ruiz-Marcellan MC, Mollejo M, Grande C, Richards KL, Hsi ED, Tzankov A, Visco C, Xu-Monette ZY, Cao X, Young KH, Conde E, Montes-Moreno S, Batlle-L?pez A, Gonz?lez de Villambros?a S, S?ez A, S?nchez L, Gonz?lez-Barca E, L?pez-Hern?ndez A, Piris M?. Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker. Oncotarget. 2016 Apr 05; 7(14):18036-49. PMID: 26910115; PMCID: PMC4951269.
      Citations: 6     Fields:    Translation:Humans
    64. Xu-Monette ZY, Deng Q, Manyam GC, Tzankov A, Li L, Xia Y, Wang XX, Zou D, Visco C, Li J, Zhang L, Liang H, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Parsons BM, Wang SA, Miranda RN, Winter JN, Medeiros LJ, Li Y, Young KH, Dybk?r K, Montes-Moreno S, Ferreri AJ, M?ller MB, Piris MA. Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2016 07 15; 22(14):3593-605. PMID: 26927665; PMCID: PMC4947447.
      Citations: 17     Fields:    Translation:Humans
    65. Xu-Monette ZY, Zhang S, Li X, Manyam GC, Wang XX, Xia Y, Visco C, Tzankov A, Zhang L, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Zhao X, Parsons BM, Winter JN, Piris MA, Medeiros LJ, Young KH, Ferreri AJ, M?ller MB. p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. Aging (Albany NY). 2016 Feb; 8(2):345-65. PMID: 26878872; PMCID: PMC4789587.
      Citations: 14     Fields:    Translation:HumansCells
    66. Ye Q, Xu-Monette ZY, Tzankov A, Deng L, Wang X, Manyam GC, Visco C, Montes-Moreno S, Zhang L, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Parsons BM, Piris MA, Winter JN, Medeiros LJ, Hu S, Young KH, Dybk?r K, Ferreri AJ, M?ller MB. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Oncotarget. 2016 Jan 19; 7(3):2401-16. PMID: 26573234; PMCID: PMC4823044.
      Citations: 34     Fields:    Translation:Humans
    67. de Winde CM, Veenbergen S, Young KH, Xu-Monette ZY, Wang XX, Xia Y, Jabbar KJ, van den Brand M, van der Schaaf A, Elfrink S, van Houdt IS, Gijbels MJ, van de Loo FA, Bennink MB, Hebeda KM, Groenen PJ, van Krieken JH, Figdor CG, van Spriel AB. Tetraspanin CD37 protects against the development of B cell lymphoma. J Clin Invest. 2016 Feb; 126(2):653-66. PMID: 26784544; PMCID: PMC4731177.
      Citations: 21     Fields:    Translation:Animals
    68. Cao X, Medeiros LJ, Xia Y, Wang X, Thomas SK, Loghavi S, Li X, Shah JJ, Gustafson SA, Weber DM, Miranda RN, Xu-Monette ZY, Orlowski RZ, Young KH. Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leuk Lymphoma. 2016 May; 57(5):1104-13. PMID: 26421453.
      Citations: 10     Fields:    Translation:Humans
    69. Xu-Monette ZY, Dabaja BS, Wang X, Tu M, Manyam GC, Tzankov A, Xia Y, Zhang L, Sun R, Visco C, Dybkaer K, Yin L, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Parsons BM, Zhao X, Winter JN, McDonnell TJ, Miranda RN, Li Y, Medeiros LJ, Young KH, Ferreri AJ, M?ller MB, Piris MA. Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol. 2015 Dec; 28(12):1555-73. PMID: 26541272.
      Citations: 21     Fields:    Translation:HumansCells
    70. Li L, Xu-Monette ZY, Ok CY, Tzankov A, Manyam GC, Sun R, Visco C, Zhang M, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Wang J, Parsons BM, Winter JN, Piris MA, Pham LV, Medeiros LJ, Young KH, Ferreri AJ, M?ller MB. Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. Oncotarget. 2015 Sep 15; 6(27):23157-80. PMID: 26324762; PMCID: PMC4695110.
      Citations: 21     Fields:    Translation:HumansCells
    71. Kanagal-Shamanna R, Xu-Monette ZY, Miranda RN, Dogan A, Zou D, Luthra R, Weber DM, O'Malley DP, Jorgensen JL, Khoury JD, Bueso-Ramos CE, Orlowski RZ, Medeiros LJ, Young KH. Crystal-storing histiocytosis: a clinicopathological study of 13 cases. Histopathology. 2016 Mar; 68(4):482-91. PMID: 26118455; PMCID: PMC4704983.
      Citations: 20     Fields:    Translation:HumansCells
    72. Liu Z, Xu-Monette ZY, Cao X, Manyam GC, Wang X, Tzankov A, Xia Y, Li X, Visco C, Sun R, Zhang L, Montes-Moreno S, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Parsons BM, Piris MA, Winter JN, O'Malley DP, Medeiros LJ, Young KH, Dybk?r K, Ferreri AJ, M?ller MB. Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. Mod Pathol. 2015 Oct; 28(10):1297-314. PMID: 26248897.
      Citations: 9     Fields:    Translation:HumansCells
    73. Ok CY, Xu-Monette ZY, Li L, Manyam GC, Montes-Moreno S, Tzankov A, Visco C, Routbort MJ, Zhang L, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Parsons BM, Rao H, Winter JN, Piris MA, Wang SA, Medeiros LJ, Young KH, Dybk?r K, Ferreri AJ, M?ller MB. Evaluation of NF-?B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. Mod Pathol. 2015 Sep; 28(9):1202-13. PMID: 26111978.
      Citations: 11     Fields:    Translation:HumansCells
    74. Cao X, Ye Q, Orlowski RZ, Wang X, Loghavi S, Tu M, Thomas SK, Shan J, Li S, Qazilbash M, Yin CC, Weber D, Miranda RN, Xu-Monette ZY, Medeiros LJ, Young KH. Waldenstr?m macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. J Hematol Oncol. 2015 Jun 24; 8:74. PMID: 26104577; PMCID: PMC4487966.
      Citations: 2     Fields:    Translation:Humans
    75. Ok CY, Ye Q, Li L, Manyam GC, Deng L, Goswami RR, Wang X, Montes-Moreno S, Visco C, Tzankov A, Dybkaer K, Zhang L, Abramson J, Sohani AR, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Zhang S, Parsons BM, Xu M, Winter JN, Piris MA, Xu-Monette ZY, Medeiros LJ, Young KH, Ferreri AJ, M?ller MB. Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary? Oncotarget. 2015 Jun 10; 6(16):13933-45. PMID: 26101854; PMCID: PMC4546442.
      Citations: 15     Fields:    Translation:HumansAnimals
    76. Xu-Monette ZY, Tu M, Jabbar KJ, Cao X, Tzankov A, Visco C, Nagarajan L, Cai Q, Montes-Moreno S, An Y, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Zhao X, Farnen JP, Winter JN, Piris MA, Miranda RN, Medeiros LJ, Young KH, Ferreri AJ, M?ller MB. Erratum: Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget. 2015 Jun 10; 6(16):14720. PMID: 26116824; PMCID: PMC4546500.
      Citations: 1     Fields:    
    77. Brauner S, Zhou W, Backlin C, Green TM, Folkersen L, Ivanchenko M, Xu-Monette ZY, Young KH, Enblad G, Baecklund E, Wahren-Herlenius M, L?fstr?m B, M?ller Pedersen L, Boe M?ller M, Sundstr?m C. Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B-cell lymphoma patients with and without rheumatic disease. J Intern Med. 2015 Sep; 278(3):323-32. PMID: 25880119.
      Citations: 19     Fields:    Translation:HumansCells
    78. Ma X, Conklin DJ, Li F, Dai Z, Hua X, Li Y, Xu-Monette ZY, Young KH, Xiong W, Wysoczynski M, Sithu SD, Srivastava S, Bhatnagar A, Li Y. The oncogenic microRNA miR-21 promotes regulated necrosis in mice. Nat Commun. 2015 May 20; 6:7151. PMID: 25990308; PMCID: PMC4440243.
      Citations: 43     Fields:    Translation:Animals
    79. Falgreen S, Young KH, Xu-Monette ZY, El-Galaly TC, Laursen MB, Kjeldsen MK, Schmitz A, Nyegaard M, Johnsen HE, Dybk?r K, B?dker JS, B?gsted M. Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models. BMC Cancer. 2015 Apr 08; 15:235. PMID: 25881228; PMCID: PMC4396063.
      Citations: 28     Fields:    Translation:HumansCells
    80. Dybk?r K, B?gsted M, Falgreen S, B?dker JS, Kjeldsen MK, Schmitz A, Bilgrau AE, Xu-Monette ZY, Li L, Bergkvist KS, Laursen MB, Rodrigo-Domingo M, Marques SC, Rasmussen SB, Nyegaard M, Gaihede M, M?ller MB, Samworth RJ, Shah RD, Johansen P, El-Galaly TC, Young KH, Johnsen HE. Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis. J Clin Oncol. 2015 Apr 20; 33(12):1379-88. PMID: 25800755; PMCID: PMC4397280.
      Citations: 56     Fields:    Translation:HumansCells
    81. Chen J, Xu-Monette ZY, Deng L, Shen Q, Manyam GC, Martinez-Lopez A, Zhang L, Montes-Moreno S, Visco C, Tzankov A, Yin L, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Zhao X, Farnen JP, Winter JN, Piris MA, Pham L, Young KH, Ferreri AJ, M?ller MB. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. Oncotarget. 2015 Mar 20; 6(8):5597-614. PMID: 25704881; PMCID: PMC4467389.
      Citations: 36     Fields:    Translation:HumansCells
    82. Xu-Monette ZY, Tu M, Jabbar KJ, Cao X, Tzankov A, Visco C, Nagarajan L, Cai Q, Montes-Moreno S, An Y, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Zhao X, Farnen JP, Winter JN, Piris MA, Miranda RN, Medeiros LJ, Young KH, Ferreri AJ, M?ller MB. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget. 2015 Mar 20; 6(8):5615-33. PMID: 25760242; PMCID: PMC4467390.
      Citations: 23     Fields:    Translation:Humans
    83. Yu H, Yue X, Zhao Y, Li X, Wu L, Zhang C, Liu Z, Lin K, Xu-Monette ZY, Young KH, Liu J, Shen Z, Feng Z, Hu W. LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers. Nat Commun. 2014 Oct 17; 5:5218. PMID: 25323535; PMCID: PMC4203416.
      Citations: 78     Fields:    Translation:HumansAnimalsCells
    84. Liu J, Zhang C, Wang XL, Ly P, Belyi V, Xu-Monette ZY, Young KH, Hu W, Feng Z. E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis. Cell Death Differ. 2014 Nov; 21(11):1792-804. PMID: 25146927; PMCID: PMC4211364.
      Citations: 63     Fields:    Translation:HumansAnimalsCells
    85. Ok CY, Chen J, Xu-Monette ZY, Tzankov A, Manyam GC, Li L, Visco C, Montes-Moreno S, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Zhao X, Ponzoni M, Bertoni F, Farnen JP, Piris MA, Winter JN, Medeiros LJ, Young KH, Dybk?r K, Ferreri AJ, M?ller MB. Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. Clin Cancer Res. 2014 Oct 01; 20(19):5113-23. PMID: 25124685; PMCID: PMC4184926.
      Citations: 33     Fields:    Translation:HumansCells
    86. Gordon MW, Yan F, Zhong X, Mazumder PB, Xu-Monette ZY, Zou D, Young KH, Ramos KS, Li Y. Regulation of p53-targeting microRNAs by polycyclic aromatic hydrocarbons: Implications in the etiology of multiple myeloma. Mol Carcinog. 2015 Oct; 54(10):1060-9. PMID: 24798859; PMCID: PMC4223015.
      Citations: 24     Fields:    Translation:HumansCells
    87. Wang S, Medeiros LJ, Xu-Monette ZY, Zhang S, O'Malley DP, Orazi A, Zuo Z, Bueso-Ramos CE, Yin CC, Liu Z, Miranda RN, Young KH. Epstein-Barr virus-positive nodular lymphocyte predominant Hodgkin lymphoma. Ann Diagn Pathol. 2014 Aug; 18(4):203-9. PMID: 24852241.
      Citations: 9     Fields:    Translation:Humans
    88. Ok CY, Xu-Monette ZY, Tzankov A, O'Malley DP, Montes-Moreno S, Visco C, Dybkaer K, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Han van Krieken J, Ponzoni M, Farnen JP, Piris MA, Winter JN, Medeiros LJ, Young KH, M?ller MB. Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Cancer. 2014 Jun 15; 120(12):1818-29. PMID: 24648050.
      Citations: 13     Fields:    Translation:HumansAnimals
    89. Ok CY, Li L, Xu-Monette ZY, Visco C, Tzankov A, Manyam GC, Montes-Moreno S, Dybkaer K, Dybaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Chen J, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ai W, Ponzoni M, Farnen JP, Bueso-Ramos CE, Miranda RN, Winter JN, Piris MA, Medeiros LJ, Young KH, Ferreri AJ, M?ller MB. Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Clin Cancer Res. 2014 May 01; 20(9):2338-49. PMID: 24583797; PMCID: PMC4014309.
      Citations: 51     Fields:    Translation:HumansCells
    90. Tzankov A, Xu-Monette ZY, Gerhard M, Visco C, Dirnhofer S, Gisin N, Dybkaer K, Orazi A, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Ponzoni M, Ye Q, Winter JN, Farnen JP, You MJ, McDonnell T, Medeiros LJ, Young KH, Ferreri AJ, Piris MA, M?ller MB. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol. 2014 Jul; 27(7):958-71. PMID: 24336156.
      Citations: 48     Fields:    Translation:Humans
    91. Miranda RN, Aladily TN, Prince HM, Kanagal-Shamanna R, de Jong D, Fayad LE, Amin MB, Haideri N, Bhagat G, Brooks GS, Shifrin DA, O'Malley DP, Cheah CY, Bacchi CE, Gualco G, Li S, Keech JA, Hochberg EP, Carty MJ, Hanson SE, Mustafa E, Sanchez S, Manning JT, Xu-Monette ZY, Miranda AR, Fox P, Bassett RL, Castillo JJ, Beltran BE, de Boer JP, Chakhachiro Z, Ye D, Clark D, Young KH, Medeiros LJ. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol. 2014 Jan 10; 32(2):114-20. PMID: 24323027; PMCID: PMC4062709.
      Citations: 96     Fields:    Translation:Humans
    92. Chou FP, Chen YW, Zhao XF, Xu-Monette ZY, Young KH, Gartenhaus RB, Wang JK, Kataoka H, Zuo AH, Barndt RJ, Johnson M, Lin CY. Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas. Am J Pathol. 2013 Oct; 183(4):1306-17. PMID: 24070417; PMCID: PMC3791685.
      Citations: 19     Fields:    Translation:HumansAnimalsCells
    93. Wang S, Tzankov A, Xu-Monette ZY, Hoeller S, Wang SA, Richards KL, Zhang S, Said JW, Medeiros LJ, Young KH. Clonally related composite follicular lymphoma and mantle cell lymphoma with clinicopathologic features and biological implications. Hum Pathol. 2013 Dec; 44(12):2658-67. PMID: 24071012.
      Citations: 5     Fields:    Translation:Humans
    94. Xu-Monette ZY, Tzankov A, Montes-Moreno S, Hu W, Manyam GC, Kristensen L, Fan L, Visco C, Dybkaer K, Chiu A, Tam W, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Wu L, Zhao X, Bueso-Ramos CE, Wang SA, Go RS, Li Y, Winter JN, Piris MA, Medeiros LJ, Young KH, M?ller MB, Ferreri AJ. MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013 Oct 10; 122(15):2630-40. PMID: 23982177; PMCID: PMC3952598.
      Citations: 25     Fields:    Translation:Humans
    95. Deng L, Xu-Monette ZY, Loghavi S, Manyam GC, Xia Y, Visco C, Huh J, Zhang L, Zhai Q, Wang Y, Qiu L, Chiu A, Perry AM, Zhang S, Tzankov A, Rao H, Abramson J, Sohani AR, Xu M, Hsi ED, Zhu J, Ponzoni M, Wang S, Li L, Zhang M, Ferreri AJ, Parsons BM, Li Y, Piris MA, Medeiros LJ, Young KH, Dybk?r K. Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium. Leukemia. 2016 Feb; 30(2):361-72. PMID: 26308769.
      Citations: 22     Fields:    Translation:Humans
    96. Frei E, Visco C, Xu-Monette ZY, Dirnhofer S, Orazi A, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Go RS, Piris MA, Young KH, Tzankov A, Dybk?r K, M?ller MB. Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. J Clin Pathol. 2013 Nov; 66(11):956-61. PMID: 23775435.
      Citations: 9     Fields:    Translation:Humans
    97. Li Y, Gordon MW, Xu-Monette ZY, Visco C, Tzankov A, Zou D, Qiu L, Montes-Moreno S, Dybkaer K, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huang Q, Ai W, Ponzoni M, Winter JN, Go RS, Piris MA, Wu L, Wang M, Ramos KS, Medeiros LJ, Young KH, Ferreri AJ, M?ller MB. Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013 May 30; 121(22):4529-40. PMID: 23515929; PMCID: PMC3668486.
      Citations: 16     Fields:    Translation:HumansCells
    98. Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, Liu WM, Visco C, Li Y, Miranda RN, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Zhao X, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Zhou F, Slack GW, Gascoyne RD, Tu M, Variakojis D, Chen W, Go RS, Piris MA, Medeiros LJ, Young KH, Ferreri AJ, M?ller MB. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013 May 16; 121(20):4021-31; quiz 4250. PMID: 23449635; PMCID: PMC3709650.
      Citations: 249     Fields:    Translation:HumansCells
    99. Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, Liu WM, Miranda RN, Zhang L, Montes-Moreno S, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Han van Krieken J, Huang Q, Huh J, Ai W, Ponzoni M, Zhao X, Winter JN, Zhang M, Li L, Piris MA, Li Y, Go RS, Wu L, Medeiros LJ, Young KH, Dybk?r K, Ferreri AJ, M?ller MB. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013 Apr 04; 121(14):2715-24. PMID: 23343832; PMCID: PMC3700465.
      Citations: 64     Fields:    Translation:HumansCells
    100. Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu WM, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Zhao XF, Choi WW, Zhao X, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Zhou F, Kahl BS, Winter JN, Xu W, Li J, Go RS, Li Y, Piris MA, Miranda RN, Abruzzo LV, Medeiros LJ, Young KH, Ferreri AJ, M?ller MB. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012 Nov 08; 120(19):3986-96. PMID: 22955915; PMCID: PMC3496956.
      Citations: 141     Fields:    Translation:Humans
    101. Hoeller S, Zhou Y, Kanagal-Shamanna R, Xu-Monette ZY, Hoehn D, Bihl M, Swerdlow SH, Rosenwald A, Ott G, Said J, Dunphy CH, Bueso-Ramos CE, Lin P, Wang M, Miranda RN, Tzankov A, Medeiros LJ, Young KH. Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study. Hum Pathol. 2013 Jan; 44(1):110-21. PMID: 22944294; PMCID: PMC3640316.
      Citations: 9     Fields:    Translation:Humans
    102. Visco C, Tzankov A, Xu-Monette ZY, Miranda RN, Tai YC, Li Y, Liu WM, d'Amore ES, Li Y, Montes-Moreno S, Chiu A, Orazi A, Zu Y, Bhagat G, Wang HY, Dunphy CH, His ED, Zhao XF, Choi WW, Zhao X, van Krieken JH, Huang Q, Ai W, O'Neill S, Ponzoni M, Ferreri AJ, Kahl BS, Winter JN, Go RS, Dirnhofer S, Piris MA, Wu L, Medeiros LJ, Young KH, Dybk?r K, M?ller MB. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica. 2013 Feb; 98(2):255-63. PMID: 22929980; PMCID: PMC3561433.
      Citations: 64     Fields:    Translation:HumansCells
    103. Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, Nielsen O, Gadeberg OV, Mourits-Andersen T, Frederiksen M, Green TM, Pedersen LM, M?ller MB. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012 Oct 01; 30(28):3460-7. PMID: 22665537.
      Citations: 239     Fields:    Translation:Humans
    104. Xu-Monette ZY, Young KH. The TP53 tumor suppressor and autophagy in malignant lymphoma. Autophagy. 2012 May 01; 8(5):842-5. PMID: 22498492; PMCID: PMC3378422.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    105. Green TM, Nielsen O, de Stricker K, Xu-Monette ZY, Young KH, M?ller MB. High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. Am J Surg Pathol. 2012 Apr; 36(4):612-9. PMID: 22314191.
      Citations: 32     Fields:    Translation:HumansCells
    106. Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Tzankov A, Wen W, Liu WM, Kahl BS, d'Amore ES, Montes-Moreno S, Chiu A, Tam W, Orazi A, Zu Y, Bhagat G, Winter JN, Wang HY, O'Neill S, Dunphy CH, Hsi ED, Zhao XF, Go RS, Choi WW, Zhou F, Czader M, Tong J, Zhao X, van Krieken JH, Huang Q, Ai W, Etzell J, Ponzoni M, Ferreri AJ, Piris MA, Bueso-Ramos CE, Medeiros LJ, Wu L, Young KH, Dybk?r K, M?ller MB. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia. 2012 Sep; 26(9):2103-13. PMID: 22437443; PMCID: PMC3637886.
      Citations: 147     Fields:    Translation:Humans
    107. Xu-Monette ZY, Medeiros LJ, Li Y, Orlowski RZ, Andreeff M, Bueso-Ramos CE, Greiner TC, McDonnell TJ, Young KH. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood. 2012 Apr 19; 119(16):3668-83. PMID: 22275381; PMCID: PMC3335376.
      Citations: 65     Fields:    Translation:HumansCells
    108. Montes-Moreno S, Martinez N, Rodriguez ME, Saez A, Gomez G, Pisano DG, Conde E, Gonzalez-Barca E, Lopez A, Mollejo M, Grande C, Martinez MA, Dunphy C, Hsi ED, Rocque GB, Chang J, Go RS, Visco C, Xu-Monette Z, Young KH, Piris MA, Sanchez-Espiridi?n B, D?az Uriarte R, Montalb?n C, Garc?a JF. miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. Blood. 2011 Jul 28; 118(4):1034-40. PMID: 21633089.
      Citations: 36     Fields:    Translation:Humans
    109. Visco C, Hoeller S, Malik JT, Xu-Monette ZY, Wiggins ML, Liu J, Sanger WG, Liu Z, Chang J, Ranheim EA, Gradowski JF, Serrano S, Wang HY, Liu Q, Dave S, Olsen B, Gascoyne RD, Campo E, Swerdlow SH, Chan WC, Tzankov A, Young KH. Molecular characteristics of mantle cell lymphoma presenting with clonal plasma cell component. Am J Surg Pathol. 2011 Feb; 35(2):177-89. PMID: 21263238; PMCID: PMC3079277.
      Citations: 8     Fields:    Translation:HumansCells
    110. Rossi D, Spina V, Deambrogi C, Rasi S, Laurenti L, Stamatopoulos K, Arcaini L, Lucioni M, Rocque GB, Xu-Monette ZY, Visco C, Chang J, Chigrinova E, Forconi F, Marasca R, Besson C, Papadaki T, Paulli M, Larocca LM, Pileri SA, Gattei V, Bertoni F, Young KH, Gaidano G, Fo? R. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011 Mar 24; 117(12):3391-401. PMID: 21266718.
      Citations: 95     Fields:    Translation:Humans
    111. Rasi S, Spina V, Bruscaggin A, Vaisitti T, Tripodo C, Forconi F, De Paoli L, Fangazio M, Sozzi E, Cencini E, Laurenti L, Marasca R, Visco C, Xu-Monette ZY, Gattei V, Young KH, Malavasi F, Deaglio S, Gaidano G, Rossi D. A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol. 2011 Feb; 152(3):284-94. PMID: 21121903.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    112. Erratum. Leukemia. 28:980.
    113. Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?. Oncotarget. 6:13933-13945.
    114. LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers. Nature Communications. 5.
    115. Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. Oncotarget. 6:23157-23180.
    116. Crystal-storing histiocytosis. Histopathology. 68:482-491.
    117. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. Leukemia.
    118. Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models. BMC Cancer. 15.
    119. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget. 6:5615-5633.
    120. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. Oncotarget. 6:5597-5614.
    121. Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology. Leukemia and Lymphoma. 1-9.
    122. Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B-cell lymphoma patients with and without rheumatic disease. Journal of Internal Medicine.
    123. Clinical and biologic significance of MYC genetic mutations in de novo diffuse large B-cell lymphoma. Clinical Cancer Research. 22:3593-3605.
    124. Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leukemia and Lymphoma. 1-10.
    125. Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Modern Pathology. 28:1555-1573.
    126. The oncogenic microRNA miR-21 promotes regulated necrosis in mice. Nature Communications. 6.
    127. Erratum. Clinical Cancer Research. 20:4974.
    128. Erratum to Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries [Oncotarget, 8, (2015), 5615-5633]. Oncotarget. 6:14720.
    129. Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. Modern Pathology. 28:1297-1314.
    130. Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. Modern Pathology. 28:1202-1213.
    131. Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era. Leukemia.
    132. Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy. Oncotarget. 7:18036-18049.
    133. Tetraspanin CD37 protects against the development of B cell lymphoma. Journal of Clinical Investigation. 126:653-666.
    134. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Oncotarget. 7:2401-2416.
    135. Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. Journal of Hematology and Oncology. 8.
    136. Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma. Oncotarget. 7:80599-80611.
    137. Age cutoff for epstein-barr virus-positive diffuse large B-cell lymphoma - is it necessary?. Oncotarget. 6:13935-13946.
    138. p63 expression confers significantly better survival outcomes in highrisk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. Aging. 8:345-365.
    XU-MONETTE's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (397)
    Explore
    _
    Co-Authors (49)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _